| Literature DB >> 22958469 |
Lauren R Jackson1, Char E Farin, Scott Whisnant.
Abstract
Mastitis or other infectious diseases have been related to reduced fertility in cattle. Inflammatory cytokines such as tumor necrosis factor α (TNFα) are released in response to infection and may have negative effects on embryo development. In the current study the effect of exposure to TNFα on the development of in vitro fertilized bovine embryos was examined. Indomethacin, a prostaglandin synthesis inhibitor, was used to determine if blockade of prostaglandin synthesis would alter the effects of TNFα. Ovaries were obtained from a local abattoir and immature COC were isolated from 2-10 mm follicles, in vitro matured and fertilized. After fertilization, groups of presumptive zygotes were randomly placed into either control development medium, medium containing 25 ng/mL TNFα or medium containing 25 ng/mL TNFα plus 1 μg/mL indomethacin. The proportion of blastocysts formed was assessed at day 7 of culture. Fewer embryos exposed to TNFα alone reached the blastocyst stage (17.5 ± 2.4%, P < 0.01) compared with controls (30.5 ± 2.4%) or embryos developed in TNFα plus indomethacin (25.8 ± 2.8%). There was no difference between control embryos and embryos developed in TNFα plus indomethacin. These results indicate that TNFα is inhibitory to the in vitro development of bovine embryos and that this inhibition may be mediated by prostaglandins because it can be blocked by indomethacin.Entities:
Year: 2012 PMID: 22958469 PMCID: PMC3436611 DOI: 10.1186/2049-1891-3-7
Source DB: PubMed Journal: J Anim Sci Biotechnol ISSN: 1674-9782
Figure 1Comparison of the effects of control medium (CON, 0 ng/mL TNFα, n = 4 replicates, 120 embryos), and addition of 25 ng/mL TNFα (n = 4 replicates, 130 embryos) or 25 ng/mL TNFα plus 1 ug/mL indomethacin (n = 4 replicates, 130 embryos) to medium on the percentage of bovine embryos reaching the blastocyst stage at 168 h post-insemination.
Percentage of embryos that reached the blastocyst stage that were classified as early blastocysts (EB), mid blastocyst (MB), expanded blastocyst (ExB), or hatched blastocyst (HB) at 168 h post-insemination.
| Treatment | EB | MB | ExB | HB |
|---|---|---|---|---|
| Control n = 4 replicates, 120 embryos | 64.3 ± 3.2% | 26.2 ± 2.2% | 9.5 ± 0.6% | 0 |
| 25 ng/mL TNFα n = 4 replicates, 130 embryos | 68.8 ± 3.4% | 31.2 ± 2.4% | 0 | 0 |
| 25 ng/mL TNFα plus 1 μg/mL Indomethacin n = 4 replicates, 130 embryos | 40.3 ± 2.5% | 43.6 ± 2.5% | 16.1 ± 1.4% | 0 |